Biomerica Launches AI-Backed inFoods庐 IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes
Biomerica (Nasdaq: BMRA) has launched the inFoods庐 IBS Trigger Food Navigator, an AI-powered digital tool designed to enhance their existing IBS diagnostic solution. The Navigator helps patients better manage their IBS symptoms by providing smart meal suggestions and ingredient substitutions based on their personalized trigger food profile.
The company's clinical studies showed significant results, with 59.6% of treatment group patients achieving FDA's endpoint for abdominal pain reduction compared to 42.2% in the control group. Even higher success rates were observed in IBS-C (67.1%) and IBS-M (66.0%) patients.
Developed with University of Michigan dietitians, the Navigator includes features like smart food identification, AI-driven meal suggestions, and an alternative food database. The tool is provided at no additional cost to existing inFoods庐 IBS test customers and is available through healthcare providers or online for new patients.
Biomerica (Nasdaq: BMRA) ha lanciato il inFoods庐 IBS Trigger Food Navigator, uno strumento digitale basato sull'IA pensato per potenziare la loro soluzione diagnostica per l'IBS. Il Navigator aiuta i pazienti a gestire meglio i sintomi dell'IBS offrendo suggerimenti intelligenti sui pasti e sostituzioni di ingredienti basati sul profilo personale dei cibi scatenanti.
Gli studi clinici dell'azienda hanno mostrato risultati rilevanti: il 59,6% dei pazienti del gruppo trattato ha raggiunto l'endpoint della FDA per la riduzione del dolore addominale, rispetto al 42,2% del gruppo di controllo. Tassi ancora pi霉 elevati sono stati osservati nei pazienti IBS-C (67,1%) e IBS-M (66,0%).
SViluppato insieme ai dietisti dell'University of Michigan, il Navigator include funzioni come l'identificazione intelligente degli alimenti, suggerimenti per i pasti guidati dall'IA e un database di alimenti alternativi. Lo strumento 猫 offerto senza costi aggiuntivi ai clienti esistenti del test inFoods庐 IBS ed 猫 disponibile tramite operatori sanitari o online per i nuovi pazienti.
Biomerica (Nasdaq: BMRA) ha lanzado el inFoods庐 IBS Trigger Food Navigator, una herramienta digital impulsada por IA dise帽ada para complementar su soluci贸n diagn贸stica para el SII. El Navigator ayuda a los pacientes a controlar mejor los s铆ntomas del SII mediante sugerencias inteligentes de comidas y sustituciones de ingredientes seg煤n su perfil personalizado de alimentos desencadenantes.
Los estudios cl铆nicos de la compa帽铆a mostraron resultados significativos: el 59,6% de los pacientes del grupo tratado alcanz贸 el objetivo de la FDA para la reducci贸n del dolor abdominal, frente al 42,2% en el grupo de control. Se observaron tasas a煤n mayores en pacientes con SII-C (67,1%) y SII-M (66,0%).
Desarrollado con dietistas de la University of Michigan, el Navigator incluye funciones como identificaci贸n inteligente de alimentos, sugerencias de comidas impulsadas por IA y una base de datos de alimentos alternativos. La herramienta se ofrece sin coste adicional a los clientes existentes de la prueba inFoods庐 IBS y est谩 disponible a trav茅s de proveedores de salud o en l铆nea para nuevos pacientes.
Biomerica (Nasdaq: BMRA)電� 旮办〈鞚� IBS 歆勲嫧 靻旊（靺橃潉 臧曧檾頃橁赴 鞙勴暣 AI 旮半皹鞚� 霐旍韯� 霃勱惮鞚� inFoods庐 IBS Trigger Food Navigator毳� 於滌嫓頄堨姷雼堧嫟. Navigator電� 臧滌澑鞚� 鞙犽皽 鞁濏拡 頂勲頃勳潉 氚旐儠鞙茧 鞀る韸疙暅 鞁濎偓 鞝滌晥瓿� 鞛 雽�觳挫晥鞚� 鞝滉车頃橃棳 頇橃瀽臧� IBS 歃濎儊鞚� 雿� 鞛� 甏�毽晿霃勲 霃曥姷雼堧嫟.
須岇偓鞚� 鞛勳儊 鞐瓣惮鞐愳劀電� 鞙犾潣頃� 瓴瓣臣臧� 雮橅儉雮姷雼堧嫟. 旃橂甑� 頇橃瀽鞚� 59.6%臧� 氤淀喌 臧愳唽鞐� 雽�頃� FDA鞚� 膦呺鞝愳棎 霃勲嫭頃� 氚橂┐ 雽�臁瓣蛋鞚� 42.2%鞐� 攴胳长鞀惦媹雼�. IBS-C(67.1%)鞕� IBS-M(66.0%) 頇橃瀽鞐愳劀電� 雿� 雴掛潃 靹标车毳犾澊 甏�彀半悩鞐堨姷雼堧嫟.
氙胳嫓臧� 雽�頃欔祼(University of Michigan) 鞓侅枒靷摛瓿� 瓿惦彊 臧滊皽霅� Navigator電� 鞀る韸� 鞁濏拡 鞁濍硠, AI 旮半皹 鞁濎偓 鞝滌晥, 雽�觳� 鞁濏拡 雿办澊韯半矤鞚挫姢 霌膘潣 旮半姤鞚� 韽暔頃╇媹雼�. 鞚� 霃勱惮電� 旮办〈 inFoods庐 IBS 瓴�靷� 瓿犼皾鞐愱矊 於旉皜 牍勳毄 鞐嗢澊 鞝滉车霅橂┌, 鞁犼窚 頇橃瀽電� 鞚橂 鞝滉车鞛愲ゼ 韱淀暣 霕愲姅 鞓澕鞚胳溂搿� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Biomerica (Nasdaq: BMRA) a lanc茅 le inFoods庐 IBS Trigger Food Navigator, un outil num茅rique propuls茅 par l'IA con莽u pour compl茅ter sa solution diagnostique pour le SCI. Le Navigator aide les patients 脿 mieux g茅rer leurs sympt么mes en proposant des suggestions de repas intelligentes et des substitutions d'ingr茅dients bas茅es sur leur profil personnalis茅 d'aliments d茅clencheurs.
Les 茅tudes cliniques de la soci茅t茅 ont montr茅 des r茅sultats significatifs : 59,6 % des patients du groupe trait茅 ont atteint le crit猫re d'茅valuation de la FDA pour la r茅duction de la douleur abdominale, contre 42,2 % dans le groupe t茅moin. Des taux de r茅ussite encore plus 茅lev茅s ont 茅t茅 observ茅s chez les patients IBS-C (67,1 %) et IBS-M (66,0 %).
D茅velopp茅 avec des di茅t茅ticiens de l'University of Michigan, le Navigator inclut des fonctionnalit茅s telles que l'identification intelligente des aliments, des suggestions de repas pilot茅es par l'IA et une base de donn茅es d'alternatives alimentaires. L'outil est fourni sans co没t suppl茅mentaire aux clients existants du test inFoods庐 IBS et est disponible via les prestataires de soins ou en ligne pour les nouveaux patients.
Biomerica (Nasdaq: BMRA) hat den inFoods庐 IBS Trigger Food Navigator eingef眉hrt, ein KI-gest眉tztes digitales Werkzeug zur Erweiterung ihrer bestehenden IBS-Diagnosel枚sung. Der Navigator unterst眉tzt Patienten dabei, ihre IBS-Symptome besser zu managen, indem er smarte Mahlzeitenvorschl盲ge und Zutatenersatz basierend auf ihrem individuellen Trigger-Food-Profil anbietet.
Die klinischen Studien des Unternehmens zeigten signifikante Ergebnisse: 59,6% der Patienten in der Behandlungsgruppe erreichten den von der FDA definierten Endpunkt zur Reduktion von Bauchschmerzen, verglichen mit 42,2% in der Kontrollgruppe. Noch h枚here Erfolgsraten wurden bei IBS-C (67,1%) und IBS-M (66,0%) beobachtet.
Entwickelt mit Ern盲hrungsberater:innen der University of Michigan, umfasst der Navigator Funktionen wie intelligente Lebensmittelerkennung, KI-gest眉tzte Mahlzeitenvorschl盲ge und eine Datenbank mit alternativen Lebensmitteln. Das Tool wird bestehenden inFoods庐 IBS-Testkunden ohne zus盲tzliche Kosten zur Verf眉gung gestellt und ist f眉r neue Patienten 眉ber Gesundheitsanbieter oder online erh盲ltlich.
- Strong clinical trial results showing 59.6% success rate in treatment group vs 42.2% in control group
- Even higher efficacy in specific IBS subtypes (67.1% for IBS-C and 66.0% for IBS-M)
- Large addressable market of 40 million adults in U.S. alone
- No additional cost for existing customers, enhancing product value proposition
- Collaboration with University of Michigan dietitians adds credibility
- No direct revenue impact disclosed from the Navigator launch
- Requires active participation from healthcare providers for new patient acquisition
Insights
Biomerica's new AI tool enhances their IBS diagnostic platform, potentially boosting adoption in the massive IBS market while improving patient outcomes.
Biomerica's launch of the AI-backed inFoods庐 IBS Trigger Food Navigator represents a strategic enhancement to their existing diagnostic platform. This digital companion tool addresses one of the most critical challenges in IBS management: patient compliance with dietary modifications. By facilitating adherence to personalized elimination plans, Biomerica is tackling a key barrier to treatment success.
The clinical data presented is particularly compelling. The 59.6% response rate in the treatment group (versus 42.2% in control) for abdominal pain reduction meets the FDA's endpoint criteria. Even more impressive are the subgroup analyses showing 67.1% efficacy in IBS-C patients and 66.0% in IBS-M patients compared to much lower rates in control groups. These statistically significant outcomes published in Gastroenterology validate their approach.
What's commercially significant is how this enhancement creates a no-additional-cost value proposition for existing customers while potentially driving new test orders. The massive addressable market of 40 million U.S. adults with IBS provides substantial growth runway. By developing this tool with University of Michigan dietitians, Biomerica adds clinical credibility while creating a practical tool that extends beyond the initial diagnostic test into ongoing patient care.
The technology's ability to generate personalized, targeted dietary plans (eliminating only 2-4 trigger foods) represents a significant competitive advantage over broad elimination diets, addressing a key pain point in IBS management while potentially improving both patient outcomes and provider satisfaction.
- New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods庐 IBS testing
- IBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwide
IRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods庐 IBS Trigger Food Navigator, a comprehensive AI-backed digital companion tool designed to better enable patient dietary compliance and improve treatment success for individuals with Irritable Bowel Syndrome (IBS).
The inFoods庐 IBS test identifies, on average, two to four specific foods that trigger a patient鈥檚 IBS symptoms, leading to a simple, highly targeted and actionable dietary plan. The new AI-backed Trigger Food Navigator builds on this therapeutic technology by making it even easier for patients to follow their personalized dietary plan through smart meal suggestions, ingredient substitutions, and simplified meal planning tools.
Simplifying Dietary Adherence for Lasting Relief
Because the inFoods庐 IBS test pinpoints only a few trigger foods, most patients can continue enjoying the majority of the foods currently in their diets, with small adjustments. This is vastly easier for patients than traditional restrictive diets that often eliminate entire food categories.
鈥淯nlike broad elimination diets, inFoods IBS has the ability to identify select and specific IBS trigger foods, which makes compliance more achievable,鈥� said Zack Irani, CEO of Biomerica. 鈥淭he new AI-backed Trigger Food Navigator takes this one step further by guiding patients through everyday food choices and offering easy substitutions. This empowers patients to stick with their personalized plan, leading to greater adherence, better symptom relief, and a significant improvement in quality of life 鈥� all while strengthening the relationship between patients and their healthcare providers.鈥�
Clinical Results
Findings from the pivotal inFoods庐 IBS clinical study and a follow-up patient success study confirmed significant symptom relief, including improvements in bloating, abdominal pain, and overall quality of life. In the largest study of its kind, recently published in the June 2025 issue of Gastroenterology, inFoods IBS demonstrated the following statistically significant outcomes:
59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA鈥檚 endpoint for abdominal pain reduction, compared to42.2% in the control group.- Among IBS-C patients,
67.1% of patients in the treatment group vs.35.8% in the control group. - Among IBS-M patients,
66.0% of patients in the treatment group vs.29.5% in the control group.
Key Features of the AI-Backed inFoods庐 IBS Trigger Food Navigator
Developed in collaboration with leading dietitians from the University of Michigan, ensuring accurate, expert-backed dietary guidance, the inFoods IBS trigger Food Navigator offers:
- Smart Food Identification 鈥� Patients can instantly check whether a meal contains their unique trigger foods.
- AI-Driven Personalized Meal Suggestions 鈥� Curated meal recommendations tailored to individual dietary restrictions.
- Alternative Food Database 鈥� Understanding of hidden or alternative ingredient names on food labels to avoid accidental consumption.
- Meal Planning & Export 鈥� Saving and exporting of favorite meals plans as shareable PDFs.
Benefits for Patients and Providers
- Improved Patient Compliance: Makes dietary changes simple, achievable and sustainable.
- Better Treatment Outcomes: Leads to greater and lasting symptom relief.
- Reduced Anxiety: Helps patients confidently navigate food choices and substitutions.
- Extended Care Between Visits: Enhances patient-provider relationships by supporting patients outside the clinic.
- Improved Quality of Life: Empowers patients to live with fewer symptoms and less disruption, vastly improving quality of life.
Access and Integration
The Navigator is included at no additional cost for patients who have already purchased the inFoods庐 IBS test. Access is activated using a purchase confirmation code. For new patients, the inFoods庐 IBS test and Navigator can be easily ordered through participating healthcare providers or online.
A demonstration video is available to showcase how the Navigator simplifies meal planning and enhances treatment success.
About Biomerica (NASDAQ: )
Biomerica, Inc. ( or www.inFoodsIBS.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. For more information, visit and .
About inFoods庐
inFoods庐 IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient鈥檚 immune response鈥攐ffering a non-pharmaceutical, precision-based approach to symptom relief.
A multicenter, double-blind clinical study on the inFoods庐 IBS test was published in the June issue of Gastroenterology, the top peer-reviewed GI journal. As the largest study of its kind, it demonstrated statistically significant outcomes:
59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA鈥檚 endpoint for abdominal pain reduction, compared to42.2% in the control group.- Among IBS-C patients,
67.1% of patients in the treatment group vs.35.8% in the control group. - Among IBS-M patients,
66.0% of patients in the treatment group vs.29.5% in the control group.
These results highlight inFoods庐 IBS as the only targeted therapy to demonstrate efficacy specifically in IBS-M patients, a subgroup historically underserved by existing treatments. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center.
For more information about inFoods庐 IBS, visit .
inFoods IBS is Laboratory Developed Test (LDT) used within a single laboratory that is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company鈥檚 current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company鈥檚 products and tests including, and quality, accuracy and聽efficacy of the information provided on the inFoods IBS Trigger Food Navigator system. future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company鈥檚 inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company鈥檚 products; availability of the Company鈥檚 test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversight, and the Company鈥檚 ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani聽|聽CEO
p. 949.645.2111
Source: Biomerica
FAQ
What is Biomerica's new inFoods庐 IBS Trigger Food Navigator and how does it work?
What were the clinical results for Biomerica's inFoods IBS treatment?
How much does the BMRA Navigator tool cost for existing inFoods IBS customers?
What are the key features of Biomerica's IBS Navigator platform?
How can patients access Biomerica's inFoods IBS test and Navigator?
